Method Profile
Nine separate breast, ovarian and gastric cancer cell-line spheroid models used for comparative drug-response profiling.
Compare reference anticancer agents and internally developed candidate inhibitors while accounting for model-specific culture and exposure conditions.
Four breast, three ovarian and two gastric cancer cell lines cultivated separately as low-attachment spheroids; five lines also evaluated as monolayers.
Treatment began after reproducible aggregation. Spheroid exposure lasted 14 or 21 days by line; 2D exposure lasted 72 hours. Metabolic viability assays supported concentration–response analysis.
Breast models
BT-20, HCC70, MDA-MB-453 and T47D cell lines.
Ovarian and gastric models
TOV21G, OVCAR-3 and A2780; SNU-1 and HGC-27. TOV21G required agarose under the selected conditions.
Readouts
AlamarBlue or PrestoBlue fluorescence normalized to matched untreated controls; fitted IC50 values when reliable and an integrated viability index as a supplementary response summary.
Compare drug responses within each specified line and exposure schedule. Do not attribute a 2D–3D difference solely to geometry when the treatment duration also differs.
Nine cell-line spheroids tested with six reference agents, followed by candidate CDK7 inhibitors; five lines also assessed in 2D.
Nine cell lines in 3D; five of those in 2D. Candidate-inhibitor experiments were repeated at least twice with three technical replicates per concentration.
Matched untreated wells within each model, reference agents, and 2D versus 3D conditions with different exposure durations.
Sensitivity changed by line and compound. Paclitaxel was a consistent assay control; iCDK7_1 showed relatively consistent antiproliferative activity in the tested spheroid panel.
Researchers optimized spheroids from nine breast, ovarian and gastric cancer cell lines before comparing anticancer compounds. Some 3D models appeared more sensitive than their 2D counterparts, while others appeared less sensitive; exposure times also differed.
